VRTX will conduct a Telaprevir+SoC trial in CC-variant IL28B patients that consists of only three months of total treatment (http://finance.yahoo.com/news/Vertex-Reports-First-Quarter-bw-1531348977.html?x=0&.v=1 ). This sounds like a good way to further differentiate Telaprevir from Boceprevir.